Cargando…

Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial

Recombinant tissue plasminogen activator (rt-PA) can be utilized to treat ischemic stroke with safety and effectiveness but limited by a narrow therapeutic window. In the present clinical trial among patients with stroke, we sought to evaluate the potential of fisetin to extend the therapeutic windo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Limin, Cao, Di, Wu, Huijun, Jia, Hongning, Yang, Chaoping, Zhang, Lihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829632/ https://www.ncbi.nlm.nih.gov/pubmed/31434498 http://dx.doi.org/10.1177/1076029619871359

Ejemplares similares

Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator
por: Knecht, Talia, et al.
Publicado: (2018)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Genome response to tissue plasminogen activator in experimental ischemic stroke
por: Jickling, Glen C, et al.
Publicado: (2010)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke
por: Bruce, Nhu T., et al.
Publicado: (2011)

Association of Geographical Factors With Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Kunisawa, Susumu, et al.
Publicado: (2013)

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke
por: Chaucer, Benjamin, et al.
Publicado: (2018)

The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator
por: Wu, Fei-Fan, et al.
Publicado: (2017)

New Perspectives for Fisetin
por: Grynkiewicz, Grzegorz, et al.
Publicado: (2019)

Fisetin: An anticancer perspective
por: Imran, Muhammad, et al.
Publicado: (2020)

Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial
por: Cluver, Catherine A, et al.
Publicado: (2021)

Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial
por: Ni, Jun, et al.
Publicado: (2020)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight
por: Peksa, Gary D, et al.
Publicado: (2019)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
por: Liu, Yonge, et al.
Publicado: (2020)

Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke
por: dela Peña, Ike C., et al.
Publicado: (2018)

APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
por: Hernández-Jiménez, Macarena, et al.
Publicado: (2023)

Randomized, Placebo-Controlled, Double-Blind Pilot Study of D-Cycloserine in Chronic Stroke
por: Butler, Andrew J., et al.
Publicado: (2015)

Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
por: Stemer, Andrew, et al.
Publicado: (2010)

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis
por: Li, Xueyuan, et al.
Publicado: (2023)

Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
por: Jung, Kee-Taig, et al.
Publicado: (2010)

Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger
por: Sweta, Adatia, et al.
Publicado: (2010)

Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke
por: Choi, Jay Chol, et al.
Publicado: (2015)

Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Zhang, Yi, et al.
Publicado: (2016)

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke
por: Lin, Cheryl B, et al.
Publicado: (2015)

Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection
por: Yang, Ze-song, et al.
Publicado: (2017)

Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke
por: Kanazawa, Masato, et al.
Publicado: (2017)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial
por: Gharagozli, K, et al.
Publicado: (2017)

Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial
por: Zhang, Cuie, et al.
Publicado: (2014)

Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke
por: Hasumi, Keiji, et al.
Publicado: (2021)

Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells
por: Xiao, Xue, et al.
Publicado: (2018)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Neuroendocrinal, Neurodevelopmental, and Embryotoxic Effects of Recombinant Tissue Plasminogen Activator Treatment for Pregnant Women with Acute Ischemic Stroke
por: Steinberg, Anna, et al.
Publicado: (2016)

Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke
por: Wang, Hai-rong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mvvhqikismh60dgbghmaf08vmj